240 related articles for article (PubMed ID: 37210743)
1. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
4. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
Vaduganathan M; Jhund PS; Claggett BL; Packer M; Widimský J; Seferovic P; Rizkala A; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
Eur Heart J; 2020 Jul; 41(25):2356-2362. PubMed ID: 32221596
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
8. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
10. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
[TBL] [Abstract][Full Text] [Related]
11. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Vaduganathan M; Cunningham JW; Claggett BL; Causland FM; Barkoudah E; Finn P; Zannad F; Pfeffer MA; Rizkala AR; Sabarwal S; McMurray JJV; Solomon S; Desai AS
JACC Heart Fail; 2021 May; 9(5):374-382. PubMed ID: 33839075
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
13. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
[TBL] [Abstract][Full Text] [Related]
14. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Gandotra C; Clark J; Liu Q; Senatore FF; Rose M; Zhang J; Stockbridge NL
Ther Innov Regul Sci; 2022 Jan; 56(1):4-7. PubMed ID: 34699047
[TBL] [Abstract][Full Text] [Related]
15. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
Chatur S; Vaduganathan M; Peikert A; Claggett BL; McCausland FR; Skali H; Pfeffer MA; Beldhuis IE; Kober L; Seferovic P; Lefkowitz M; McMurray JJV; Solomon SD
Eur J Heart Fail; 2022 Oct; 24(10):1906-1914. PubMed ID: 35895867
[TBL] [Abstract][Full Text] [Related]
17. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
Vaduganathan M; Claggett BL; Greene SJ; Aggarwal R; Bhatt AS; McMurray JJV; Fonarow GC; Solomon SD
JAMA Cardiol; 2021 Dec; 6(12):1415-1423. PubMed ID: 34524394
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
19. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
[TBL] [Abstract][Full Text] [Related]
20. Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial.
Fudim M; Cyr DD; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sharma K; Claggett BL; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E; Mentz RJ;
J Card Fail; 2024 May; ():. PubMed ID: 38802053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
